Procedural Sedation for Pediatric Patients With Spinal Muscular Atrophy

Sponsor

Ankara City Hospital Bilkent (Other)

Overall Status

Completed

CT.gov ID

NCT05291962

Collaborator

(none)

Enrollment

Location

Actual Duration (Days)

14.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Background and Aim: Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by progressive symmetrical weakness and atrophy of proximal muscles causing from degeneration of anterior horn cells of spinal cord. Nusinersen must be administered intrathecally and this treatment is specially for spinal muscular atrophy. Procedural sedation is commonly enough for intrathecal treatment in children. In this retrospective study, the investigators aimed to present our experience in procedural sedation for the intrathecal treatment of patients with SMA 1,2 and 3 in our hospital.

Condition or Disease	Intervention/Treatment	Phase
Muscular Atrophy, Spinal Child, Only Anesthesia	Other: Retrospective observational study

Detailed Description

Design: This research is a retrospective obsevational study. Methods: After approval Institutional Review Board, data from anesthesia charts and electronic medical records of 14 patients with SMA type I, II and III who underwent procedural sedation,such as; the demographics data of the patients (age, gender, weight, American Society of Anesthesiologist (ASA) Physical Status), which anesthetic agent was used and their doeses, during of anesthesia, presence of scoliosis, by whom the procedure was performed etc. was reviewed. All our patients with SMA type II and III who underwent intrathecal treatment are given sedation with different combination of anesthetic agent. Due to peripheral intravenous line was placed previously, intravenous induction was performed in all of our patients For procedural sedation, anesthesiologists used different combination of midazolam, ketamine, propofol, fentanyl or remifentanyl, depending on the patient's requirement. They were oxygenated with a face mask or nasal cannula while their spontaneous breathing continues. All patients were recovered in the recovery room.

Statistical analysis: The data were analyzed by using SPSS Statistics Software (SPSS 24, Chicago, IL, USA) Descriptive statistics were used in this study. Mean and standart deviation were calculated for Age (year), Weight (kilogram), Midazolam Dose (mg/kg), Fentanyl Dose (mcg/kg), Remifentanyl Dose (mcg/kg), Propofol Dose (mg/kg), Ketamine Dose (mg/kg) and Length of Stay in Recovery Room (minute) and frequency analysis were made for the number of intervention.

Study Design

Study Type:

Observational

Actual Enrollment :

14 participants

Observational Model:

Other

Time Perspective:

Retrospective

Official Title:

Procedural Sedation for Pediatric Patients With Spinal Muscular Atrophy Undergoing Intrathecal Treatment

Actual Study Start Date :

Jan 1, 2022

Actual Primary Completion Date :

Jan 31, 2022

Actual Study Completion Date :

Jan 31, 2022

Outcome Measures

Primary Outcome Measures

Procedural sedation [4 years (The data of the patients were retrospectively analyzed between July 2017 and December 2021.)]
The number of pediatric patients with SMA I,II and III who underwent intrathecal treatment required procedural sedation
Anesthetics use [4 years (The data of the patients were retrospectively analyzed between July 2017 and December 2021.)]
The anesthetic agents and their doses that used during procedure
Age [4 years (The data of the patients were retrospectively analyzed between July 2017 and December 2021.)]
Age in year
Gender [4 years (The data of the patients were retrospectively analyzed between July 2017 and December 2021.)]
Gender as female/male
Weight [4 years (The data of the patients were retrospectively analyzed between July 2017 and December 2021.)]
Weight in kilograms
American Society of Anesthesiologists (ASA) physical status [4 years (The data of the patients were retrospectively analyzed between July 2017 and December 2021.)]
ASA score
Type of SMA [4 years (The data of the patients were retrospectively analyzed between July 2017 and December 2021.)]
SMA I, SMA II and SMA III

Secondary Outcome Measures

Presence of scoliosis [4 years The data of the patients were retrospectively analyzed between July 2017 and December 2021.)(]
Yes or no
How many times intrathecal treatment was performed for each patient [4 years The data of the patients were retrospectively analyzed between July 2017 and December 2021.)]
The number of intrathecal treatments was administered for each patient over 4 years was recorded.
By whom the procedure was performed [4 years The data of the patients were retrospectively analyzed between July 2017 and December 2021.)]
It was recorded who performed the lumbar puncture procedure from a neurologist, neurosurgeon, or anesthesiologist.
Length of time spent in recovery room [4 years The data of the patients were retrospectively analyzed between July 2017 and December 2021.)]
Recovery time in minutes

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A to 18 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Pediatric patients younger than 18 years old with SMA 1,2 and 3 who were to undergo intrathecal Nusinersen treatment were included in this study.

Exclusion Criteria:

Patients whose procedures were performed under fluoroscopic guidance in the radiology unit were excluded from the study because their procedures were performed in another hospital.
Patients without a diagnosis of SMA